Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
A new chapter for biotech: Confidence returns to the market
In this article from Fierce Biotech, Chris Smyth, President of ICON Biotech outlines reasons for optimism in 2024, as the biotech sector looks to bounce back after several challenging years.
-
Revolutionising Drug Development: Key Takeaways from the ICON Biotech Survey
In this article from The Journal of mHealth, Chris Smyth, President of ICON Biotech, dissects the challenges and opportunities discovered in ICON's recent biotech sector survey. He explores strategies for accelerating the drug development process, emphasising the potential of partnerships to strategically support biotech companies, how organisations are addressing the current funding challenges and the industry’s overall commitment to addressing unmet healthcare needs.
-
ICON acquires HumanFirst to boost support for digital tools in clinical trials
This article from STAT covers ICON’s acquisition of HumanFirst, a cloud-based technology company supporting precision measurement in clinical trials. It features an interview with Andy Coravos, CEO of HumanFirst, who outlines how the acquisition will support sponsors to deploy better and more effective precision measurements into more clinical trials.
-
A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain
In an interview with PharmaVoice, Helen Yeardley, SVP, Global Clinical Operations outlines how the hiring landscape for CRAs has improved markedly, and the ongoing importance of attracting new candidates and providing training.
-
Central to the mission
In this article from Pharmaceutical Executive, Harpreet Gill, VP of Real World Solutions - Project Management, discusses the progress and challenges in advancing data-driven tools and approaches in decentralised clinical trials.
-
The CRA of the future: From ‘road warrior’ to site ‘owner’
In this article from Applied Clinical Trials, Helen Yeardley, SVP, Global Clinical Operations explores how the role of the CRA is rapidly evolving in response to changes in clinical trials. She outlines how the industry can invest in CRA talent and apply new thinking to critical areas, including site-performance management, risk management, remote monitoring, and remote data collection.
-
ICON biotech sector survey: Insights and projections shaping the industry
In this article from PM360, Chris Smyth, President of ICON Biotech, summarises the main findings from the biotech sector survey and outlines the key implications for biotech including strategic collaboration, innovation and cost optimisation.
-
Capitalising on collaboration and confidence: Survey insights and expectations for biotech in 2024
This article by Chris Smyth, President, ICON Biotech, provides an overview of the recent ICON biotech sector survey findings, and looks at the trend of biotech companies engaging earlier and more comprehensively with CROs to drive efficiencies and realise the full value of their R&D programs.
-
Optimism returns as biotech optimise R&D
In this article, Brandon Early, SVP Project Delivery, outlines some of the key findings from the ICON biotech sector survey of over 130 decision makers in small, mid-size, large biotech and VC organisations.
-
Outsourcing analytical testing: AI could transform analytical labs
In this article from Drug Development & Delivery, Suzanne Jansen, Head of QC Laboratory, discusses the importance of faster data turnaround within the analytical lab to facilitate adaptive dosing decisions that will benefit all stages of clinical trials.
